Online Mutation Report

Rapp-Hodgkin and AEC syndromes due to a new frameshift mutation in the TP63 gene

I Dianzani, E Garelli, P Gustavsson, A Carando, B Gustafsson, N Dahl, G Annerén

Key points

- TP63 gene mutations have been identified in several malformation syndromes. An apparently conclusive genotype-phenotype correlation has been deduced from the fact that they are caused by mutations in specific protein domains.
- Our investigation of three multiplex families revealed causal mutations. The family exhibiting Rapp–Hodgkin syndrome (RHS) carried a new mutation, a deletion of an A located in exon 14 (1859delA).
- This is the first demonstration that RHS is due to a p63 defect. RHS is differentiated from ankyloblepharon-ectodermal dysplasia-cleft (AEC) syndrome by the absence of ankyloblepharon filamentous adnatum. The finding of this anomaly in one patient from the RHS family suggests that AEC and RHS are the same clinical entity.

An apparently conclusive genotype-phenotype correlation has been deduced to explain the development of different syndromes (with some exceptions). All but one of the EEC mutations affect the TP63 DNA binding domain, whereas all but one of the AEC mutations are caused by missense mutations affecting the SAM domain. SHFM patients have either missense mutations in the DNA binding domain or nonsense mutations within the C terminus. Three mutations have been found in LMS patients: two frameshift mutations in exon 13 or 14, and a missense mutation in exon 4. ADULT syndrome mutations include one missense mutation in the TA2 domain located at the N terminal region of the AN isoform, and a specific missense mutation in the DNA binding domain.

EEC and SHFM missense mutations are expected to lose TA functions; AEC and LMS mutants maintain TA functions, but lose the regulatory functions ascribed to the SAM domain. ADULT and Rapp–Hodgkin syndrome are the same clinical entity. All of these hypotheses have been supported by expression of mutant proteins and analysis of their function in the laboratory or by analogy with p73 and p53 mutants. ADULT mutations are mutations that gain function, because they both activate the TA domain. These hypotheses have been supported by expression of mutant proteins and analysis of their function in the laboratory or by analogy with p73 and p53 mutants. SHFM is genetically heterogeneous: only 10% of SHFM are due to TP63. 21, 24

Rapp-Hodgkin syndrome (RHS: MIM 129400) is autosomal dominant and shares two cardinal symptoms with

increases in the number of allelic malformation syndromes (due to mutations in a single gene) have led to their classification according to their pathogenesis rather than their clinical specific phenotype. TP63 mutations have been identified in several such syndromes characterised by autosomal dominant transmission and various combinations of ectodermal dysplasia, limb malformations, and orofacial clefting.

The TP63 gene is a TP53 homologue, part of a family composed of only three members. The third member (TP73) is more similar to TP63 than to TP53 in both structure and function. Like p53, p63 has a transactivating (TA), a DNA binding (DB), and a polymerisation domain; it exerts p53-like activities in various contexts, such as binding canonical p53 sites, transactivating p53 target genes, and inducing apoptosis. Unlike TP53, which expresses one major transcript, TP63 contains four separate transcription initiation sites that direct expression of two fundamentally different isoforms. These hypotheses have been supported by expression of mutant proteins and analysis of their function in the laboratory or by analogy with p73 and p53 mutants. SHFM patients have either missense mutations in the DNA binding domain or nonsense mutations within the C terminus. Three mutations have been found in LMS patients: two frameshift mutations in exon 13 or 14, and a missense mutation in exon 4. ADULT syndrome mutations include one missense mutation in the TA2 domain located at the N terminal region of the AN isoform, and a specific missense mutation in the DNA binding domain.

EEC and SHFM missense mutations are expected to lose TA functions; AEC and LMS mutants maintain TA functions, but lose the regulatory functions ascribed to the SAM domain. ADULT and Rapp–Hodgkin syndrome are the same clinical entity. All of these hypotheses have been supported by expression of mutant proteins and analysis of their function in the laboratory or by analogy with p73 and p53 mutants. SHFM is genetically heterogeneous: only 10% of SHFM are due to TP63. 21, 24

Rapp-Hodgkin syndrome (RHS: MIM 129400) is autosomal dominant and shares two cardinal symptoms with
EEC: cleft lip / palate and ectodermal dysplasia. Its other features are hypohidrosis, a peculiar face with a narrow nose and a small mouth, short stature, hypospadias, pili torti or pili canaliculi (uncombable hair), and normal intelligence. The association of hypohidrosis, sparse hair, nail dysplasia, and cleft palate was first described by Rapp and Hodgkin in a mother and her two siblings. RHS is treated as a syndrome to be ruled out in the diagnosis of EEC, sometimes observed unaccompanied by ectrodactyly. However, the birth of a son with EEC to a woman with RHS has suggested that the two phenotypes could be allelic. Molecular analysis of TP63 has not been extensively performed to confirm or disprove this hypothesis. Finally, RGorlin lists RHS and AEC as a single clinical entity, since only the occurrence of ankyloblepharon filiforme adnatum in the latter distinguishes them. He clearly states that molecular evidence is awaited to confirm this hypothesis.

This paper describes the mutations found in three Swedish multiplex families: two had EEC, one had RHS. One patient from the RHS family had a slight ankyloblepharon on one eye at birth, and, according to Gorlin’s criteria, should be considered affected by AEC. Our work is the first to demonstrate that RHS is due to a TP63 defect and that AEC and RHS are the same clinical entity.

MATERIALS AND METHODS
Subjects
Families A and C were diagnosed and reported on by GA et al at the Department of Genetics and Pathology, Uppsala University, Sweden, and family B was diagnosed by BG at the Karolinska Institute, Stockholm, Sweden. Pedigrees are shown in fig 1 and clinical data in table 1. Informed consent was obtained from all family members before their participation.

Diagnosis of EEC syndrome was obtained following previously described diagnostic criteria. Both family B and family C included patients with the classic triad. A typical RHS was diagnosed in family A (fig 2) from the combination of ectodermal dysplasia and cleft, absence of ankyloblepharon on one eye at birth, and, according to Gorlin’s criteria, should be considered affected by AEC. Our work is the first to demonstrate that RHS is due to a TP63 defect and that AEC and RHS are the same clinical entity.

### Table 1 Clinical and molecular data in the RHS and EEC families

<table>
<thead>
<tr>
<th>Family</th>
<th>Patient</th>
<th>Gender</th>
<th>Diagnosis</th>
<th>Clinical signs</th>
<th>Mutation</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>I-2</td>
<td>Female</td>
<td>RHS or AEC</td>
<td>C palate, E, slight ankyloblepharon on right eye</td>
<td>1859 Del A</td>
</tr>
<tr>
<td>A</td>
<td>II-1</td>
<td>Female</td>
<td>RHS</td>
<td>E</td>
<td>1859 Del A</td>
</tr>
<tr>
<td>A</td>
<td>II-3</td>
<td>Female</td>
<td>RHS</td>
<td>C lip/palate, E</td>
<td>1859 Del A</td>
</tr>
<tr>
<td>B</td>
<td>II-5</td>
<td>Female</td>
<td>EEC</td>
<td>Bilateral C lip/palate, left hand S IV/V and absent II/III, right hand S II/VI with absent III/IV and clinodactyly I, both feet S III/IV and absent II/III</td>
<td>R279C</td>
</tr>
<tr>
<td>B</td>
<td>III-5</td>
<td>Male</td>
<td>EEC</td>
<td>C lip/palate, obstructed lacrimal ducts, left hand S I/II and absent III, right hand S I/II, left foot S III/IV and absent II/III</td>
<td>R279C</td>
</tr>
<tr>
<td>C</td>
<td>I-2</td>
<td>Female</td>
<td>EEC</td>
<td>Bilateral C lip/palate, sparse eye lashes and eyebrows, obstructed lacrimal ducts, bilateral clinodactyly V, hypoplastic nails</td>
<td>R304Q</td>
</tr>
<tr>
<td>C</td>
<td>II-1</td>
<td>Female</td>
<td>EEC</td>
<td>C lip/palate, hypoplastic nails, sparse hair, obstructed lacrimal ducts, right hand preaxial polydactyly, left foot postaxial polydactyly, right foot cutaneous S II/III</td>
<td>R304Q</td>
</tr>
<tr>
<td>C</td>
<td>II-2</td>
<td>Female</td>
<td>EEC</td>
<td>Bilateral C, hypoplastic nails, obstructed lacrimal ducts, right hand short distal phalanges III/IV, preaxial polydactyly, left hand absent distal phalanges, right foot cutaneous S II/III</td>
<td>R304Q</td>
</tr>
<tr>
<td>C</td>
<td>II-3</td>
<td>Male</td>
<td>EEC</td>
<td>Bilateral C lip/palate, hypoplastic nails, obstructed lacrimal ducts, right hand cutaneous S II/III and IV/V</td>
<td>R304Q</td>
</tr>
<tr>
<td>C</td>
<td>II-4</td>
<td>Male</td>
<td>EEC</td>
<td>Bilateral C lip/palate, hypoplastic nails, obstructed lacrimal ducts, bilateral hand and foot ectrodactyly, left hand cutaneous S II/III and IV/V, bilateral foot rudimentary II and III and cutaneous S III/IV</td>
<td>R304Q</td>
</tr>
</tbody>
</table>

RHS, Rapp–Hodgkin syndrome; AEC, ankyloblepharon-ectodermal dysplasia-cleft; EEC, ectodermal dysplasia, ectrodactyly, cleft lip / palate; E, ectodermal dysplasia (anhidrosis, no tears, sparse hair, pili torti / canaliculi, tooth hypoplasia, dysplastic nails); C, cleft; S, syndactyly.
cleft palate and the younger daughter had a cleft lip and palate. The mother lost her hair after recurrent scalp infections. Both she and her elder daughter had many pigmented naevi. The patients had normal nipples and the mother breastfed her children. The cleft and absence of hand and nipple anomalies excluded LMS in all patients. The absence of ankyloblepharon filiforme excluded AEC, and the patients were diagnosed as affected by RHS. However, a thorough study of the patients’ clinical histories ascertained that the mother had a slight ankyloblepharon on the right eye at birth, which was surgically treated. According to Gorlin’s criteria, she was affected by AEC.

**Segregation and mutational analysis**

Blood samples were drawn from all participants and genomic DNA extracted by standard methods. Segregation of 3q highly polymorphic markers (D3S3530 and D3S1294) were analysed by PCR amplification followed by acrylamide electrophoresis and silver staining. TP63 genomic screening was performed by PCR amplification of single exons and intron-exon boundaries, followed by sequencing using an ABI PRISM-BigDye Terminator Cycle Sequencing Ready Reaction kit and an ABI PRISM 310 Genetic Analyzer (Applied Biosystems, Warrington, UK). Each exon was sequenced twice using 5’ and 3’-primers (the primer sequence has been reported) and amino acid position was numbered according to recent literature.

Mutation segregation was ascertained by digestion with restriction enzymes. R279C (CGC -> TGC) was identified by PstI, which recognises and cuts the mutant sequence when a mutagenesis primer is used for PCR; R304Q (CGG -> CAG) was recognised by HpaII, which cuts the normal sequence.

**RESULTS**

Segregation of 3q highly polymorphic markers (D3S3530 and D3S1294) was concordant with the disease in all three families (data not shown). This suggested that RHS was allelic with EEC. Causal mutations were found: the EEC families carried mutations in the DNA binding domain of p63, namely R279C in exon 7 and R304Q in exon 8, respectively. These mutations are recurrent, since they have been found in several unrelated families. Full penetrance was always observed, although expression was variable even in the monozygotic twins of family C. This points to a stochastic event in embryo development, since the twins shared the same genetic background. Microsatellite segregation and mutation analysis showed that the mutation was a new event in the paternal meiosis of patient II-5 in family B. Grandparents were not available for the other families.

![Figure 2](image_url)  
**Figure 2**  
Facial appearance of RHS patients from Family A. The mother is wearing a wig.

![Figure 3](image_url)  
**Figure 3**  
(A) Electropherogram from RHS patient II-1. An arrow denotes the DNA change (1859delA). Sequences of the wild type and the mutant alleles are reported. (B) Predicted amino acid sequence resulting from frameshift mutations in the p63 α tail. The vertical bars denote protein portions encoded by exons 12, 13, 14. Bold type indicates the new amino acid sequence resulting from the frameshift. The associated diseases are shown.
Complete sequencing of DNA from RHS patient II-1 (family A) revealed deletion of an A at position 1859 in exon 14, within codon 620, as illustrated in fig 3(A). Deletion causes a frameshift and affects the α tail.

Exon 14 was subsequently sequenced in all the members of the family. The deletion was found in all three affected members and not in the normal sibling. This new mutation is the most 3' frameshift mutation found so far in TP63.

DISCUSSION

This paper records the identification of a mutation in TP63 in an RHS family with three affected members; the molecular basis of RHS is thus defined. There has been no previous published demonstration of the molecular basis of RHS, although a recent paper reported analysis of the TP63 gene in a sporadic patient without any mutation being disclosed. It is possible that there was a causal mutation in the introns and regulatory sequences, which were not screened in that paper.

The mother in family A had a slight ankyloblepharon of one eye at birth. According to Gorlin’s criteria, she was affected by AEC rather than RHS. Thus, our data not only allow classification of RHS among allelic syndromes due to TP63 mutations, but also confirm the hypothesis that AEC and RHS are the same clinical entity.

The 1859delA mutation found in the RHS patients predicts an abnormal α tail. Other α tail mutations have been found in patients with LMS, EEC, AEC, and SHFM, namely: a TT deletion at bases 1576–1577 in exon 13 and a deletion of two As at 1743–1744 in exon 14 in LMS patients; an insertion of an A at base 1572 of exon 13 in an EEC patient; a 1742delC in an AEC patient; and two nonsense mutations (Q634X and E639X) in SHFM patients. All these mutations affect only the α isoforms of p63, but with different molecular consequences.

The TT deletion in LMS and the A insertion in EEC are both in exon 13. They predict the use of the same frame which reveals a stop codon at base 1611 within exon 13, and an effect on the SAM domain, if expressed. The insA mutant has been expressed in the laboratory and conferred a gain of function is also expected for these mutants, if they are indeed expressed. It is intriguing that the use of the same frame by different mutations is responsible for similar phenotypes: insA and delTT for EEC and LMS, and delC and delA for AEC respectively. Thus a gain of effect on the SAM domain, if expressed. The insA mutant has been expressed in the laboratory and conferred a gain of function is also expected for these mutants, if they are indeed expressed.

Recently, an unusual mutation affecting ex 11 splicing was found in an AEC patient, IVS10-2: the skipping of exon 11 results in a frameshift. The molecular consequences are different from those expected from the α tail framshifts, because not only the α but also the β isoforms are affected by IVS10-2.

Our data show that RHS is due to a defect in TP63. Thus, the spectrum of malformation diseases due to TP63 abnormalities is further extended. We also show that RHS and AEC are probably the same clinical entity. Further studies are needed to elucidate the developmental pathways that involve the different functions of p63 isoforms. These may clarify the pathogenesis of diseases due to TP63 mutations and their apparent genotype-phenotype correlation.

ACKNOWLEDGEMENTS

We wish to thank Dr M Silengo for helpful discussion.

ELECTRONIC DATABASE INFORMATION

Accession numbers and the URL for data in this article are as follows: Online Mendelian Inheritance in Man (OMIM), http://www.ncbi.nlm.nih.gov/Omim/ for EEC (MIM 604292), for SHFM (MIM 183600), for AEC (MIM 106260), for LM (MIM 603541), for ADULT (MIM 103285), and for RHS (MIM 129400).
RHS is due to mutations in TP63.